Cerity Partners
GRCE

Cerity Partners’s Grace Therapeutics GRCE Stock Holding History

Cerity Partners’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.93M Buy
849,055
+426,323
+101% +$1.67M 0.01% 1139
2025
Q4 		$1.46M Buy
+422,732
New +$1.34M ﹤0.01% 1514

Other funds holding GRCE

EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return

Cerity Partners's GRCE Position: Q1 2026 in Review

Cerity Partners increased its Grace Therapeutics (GRCE) stake by 101% in Q1 2026, buying an estimated $1.67M and bringing the position to 849,055 shares worth $3.93M. The position accounts for 0.01% of the portfolio, ranked #1139.

Cerity Partners first reported a position in GRCE in Q4 2025 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

  • Cerity Partners held 849,055 shares of Grace Therapeutics worth $3.93M as of Q1 2026.
  • Cerity Partners bought 426,323 Grace Therapeutics shares in Q1 2026, an estimated $1.67M.
  • Grace Therapeutics made up 0.01% of Cerity Partners's portfolio in Q1 2026, its #1139 holding.
  • Cerity Partners first reported a position in Grace Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.